| Glaxo Kidney Cancer Drug Has Liver Risk, FDA Says - Bloomberg |
|
|
BloombergGlaxo's pazopanib may be “associated with a significant risk” of severe liver injury in patients with advanced renal cell carcinoma, the most-common form of ...FDA Staff Express Safety Concerns About GlaxoSmithKline's Votrient For Kidney ... read more |